Shares of WeightWatchers (WW) are climbing after the company announced a compounded GLP-1 medication starting at $129 as it seeks to make the weight-management solution "accessible and affordable."

Catalysts Hosts Seana Smith and Madison Mills report more on the story and how it can compete with GLP-1 weight-loss drugs like Novo Nordisk's (NVO) Ozempic and Eli Lilly's (LLY) Mounjaro.

For more expert insight and the latest market action, click here to watch this full episode of Catalysts.

This post was written by Melanie Riehl